PrECOG Cancer Research Group

The PrE1702 research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive in patients not participating in a clinical trial. Learn more: https://bit.ly/pre1702-study

PrE0510 is a randomized phase 2 clinical trial exploring the optimal dose of ivonescimab with carboplatin and etoposide in extensive-stage small cell lung cancer ( ). For more information: bit.ly/PrE0510

research study PrE1702, led by Dr. Suzanne Cole of UT Southwestern, aims to discover if osimertinib with or without chemotherapy has the same benefits for patients receiving treatment outside of a as for those in a trial. Learn more: https://bit.ly/pre1702-study

Dr. Taofeek Owonikoko of is leading PrE0510, a phase 2 clinical trial treating patients with extensive-stage small cell lung cancer ( ) who have not yet had systemic therapy. Learn more: bit.ly/PrE0510

How well does osimertinib—with or without chemotherapy—work to control EGFR-positive in patients not participating in a clinical trial? The PrE1702 research study aims to find out. Learn more: https://bit.ly/pre1702-study

The PrE0510 clinical trial, led by Dr. Taofeek Owonikoko of , aims to determine the optimal dose of ivonescimab in combo with carboplatin & etoposide for patients with small cell lung cancer. More: bit.ly/PrE0510

The PrE0510 clinical trial, led by Dr. Taofeek Owonikoko of , aims to determine the optimal dose of ivonescimab in combo with carboplatin & etoposide for patients with small cell lung cancer. More: https://bit.ly/PrE0510